Claims
- 1. A method for treating or preventing disorders of the respiratory tract or lung comprising the step of administering to a subject in need thereof, a therapeutically effective amount of a lipoxin analog having the formula
- 2. The method of claim 1, wherein the disorder of the respiratory tract is chronic bronchitis.
- 3. The method of claim 1, wherein the disorder of the respiratory tract is bronchiectasis.
- 4. The method of claim 1, wherein the disorder of the respiratory tract is eosinophilic lung diseases.
- 5. The method of claim 1, wherein the disorder of the respiratory tract is allergic bronchopulmonary aspergillosis.
- 6. The method of claim 1, wherein the disorder of the respiratory tract is allergic inflammation of the respiratory tract.
- 7. The method of claim 1, wherein the disorder of the respiratory tract is bronchiolitis.
- 8. The method of claim 1, wherein the disorder of the respiratory tract is bronchiolitis obliterans.
- 9. The method of claim 1, wherein the disorder of the respiratory tract is bronchiolitis obliterans with organizing pneumonia.
- 10. The method of claim 1, wherein the disorder of the respiratory tract is eosinophilic granuloma.
- 11. The method of claim 1, wherein the disorder of the respiratory tract is Wegener's granulomatosis.
- 12. The method of claim 1, wherein the disorder of the respiratory tract is sarcoidosis.
- 13. The method of claim 1, wherein the disorder of the respiratory tract is hypersensitivity pneumonitis.
- 14. The method of claim 1, wherein the disorder of the respiratory tract is idiopathic pulmonary fibrosis.
- 15. The method of claim 1, wherein the disorder of the respiratory tract is pulmonary manifestations of connective tissue disease.
- 16. The method of claim 1, wherein the disorder of the respiratory tract is acute or chronic lung injury.
- 17. The method of claim 1, wherein the disorder of the respiratory tract is adult respiratory distress syndrome.
- 18. The method of claim 1, wherein the disorder of the respiratory tract is lung injury associated with parasite infection.
- 19. The method of claim 1, wherein the disorder of the respiratory tract is chronic obstructive pulmonary disease (COPD).
- 20. The method of claim 1, wherein the disorder of the respiratory tract is aspirin-intolerant asthma.
- 21. The method of claim 1, wherein eosinophil-mediated inflammation of the lung or tissues is inhibited or prevented.
- 22. A packaged pharmaceutical composition for treating or preventing disorders of the respiratory tract or lung in a subject, comprising a container holding a therapeutically effective amount of at least one lipoxin analog having the formula
- 23. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is chronic bronchitis.
- 24. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is bronchiectasis.
- 25. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is eosinophilic lung diseases.
- 26. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is allergic bronchopulmonary aspergillosis.
- 27. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is allergic inflammation of the respiratory tract.
- 28. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is bronchiolitis.
- 29. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is bronchiolitis obliterans.
- 30. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is bronchiolitis obliterans with organizing pneumonia.
- 31. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is eosinophilic granuloma.
- 32. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is Wegener's granulomatosis.
- 33. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is sarcoidosis.
- 34. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is hypersensitivity pneumonitis.
- 35. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is idiopathic pulmonary fibrosis.
- 36. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is pulmonary manifestations of connective tissue disease.
- 37. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is acute or chronic lung injury.
- 38. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is adult respiratory distress syndrome.
- 39. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is lung injury associated with parasite infection.
- 40. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is chronic obstructive pulmonary disease (COPD).
- 41. The packaged pharmaceutical of claim 22, wherein the disorder of the respiratory tract is aspirin-intolerant asthma.
- 42. The packaged pharmaceutical of claim 22, wherein eosinophil-mediated inflammation of the lung or tissues is inhibited or prevented.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 60/338,862, filed Nov. 6, 2001, entitled “Lipoxins and Aspirin-Triggered Lipoxins and Their Stable Analogs in the Treatment of Asthma and Inflammatory Airway Diseases” and U.S. Provisional Application No. 60/391,049, filed on Jun. 24, 2001, entitled “Lipoxins and Aspirin-Triggered Lipoxins and Their Stable Analogs in the Treatment of Asthma and Inflammatory Airway Diseases” the contents of which are incorporated herein by reference.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] The work leading to this invention was supported in part by National Institutes of Health (NIH) grants GM-38765, P01-DE13499 and K08 HL03788. The U.S. Government therefore may have certain rights in the invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60391049 |
Jun 2002 |
US |
|
60338862 |
Nov 2001 |
US |